<DOC>
	<DOC>NCT01031459</DOC>
	<brief_summary>The purpose of this study is to investigate the clinical status of patients who participated in the original pivotal Betaseron study at 20 years after randomized treatment initiationStudy end-points include: 1. Mortality - All-cause mortality - Cause specific mortality - Multiple sclerosis-related mortality 2. EDSS (Expanded Disability Status Scale) 3. Cognition 4. Resource use 5. SPMS (Secondary Progressive Multiple Sclerosis) status 6. Employment history</brief_summary>
	<brief_title>Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Previously enrolled in the Betaseron pivotal study protocols TB0135686 in the US and TB0135886 in Canada (total, N=372) Patient, caregiver, or legal guardian must provide written informed consent Patient must confirm her/his ability and agreement to participate in the study at the beginning of the phone call</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>